Certara, Inc.

HMSE:700 Stock Report

Market Cap: €1.6b

Certara Valuation

Is 700 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 700 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 700 (€9.62) is trading above our estimate of fair value (€7.88)

Significantly Below Fair Value: 700 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 700?

Key metric: As 700 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 700. This is calculated by dividing 700's market cap by their current revenue.
What is 700's PS Ratio?
PS Ratio4.5x
SalesUS$372.80m
Market CapUS$1.67b

Price to Sales Ratio vs Peers

How does 700's PS Ratio compare to its peers?

The above table shows the PS ratio for 700 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.1x
NXU Nexus
4.5x9.8%€1.2b
COP CompuGroup Medical SE KGaA
0.6x1.4%€726.9m
M3V MeVis Medical Solutions
2.6xn/a€45.1m
AJ91 DocCheck
0.8xn/a€42.1m
700 Certara
4.5x9.6%€1.7b

Price-To-Sales vs Peers: 700 is expensive based on its Price-To-Sales Ratio (4.5x) compared to the peer average (2.1x).

Price to Sales Ratio vs Industry

How does 700's PS Ratio compare vs other companies in the European Healthcare Services Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
700 4.5xIndustry Avg. 2.2xNo. of Companies11PS02.44.87.29.612+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 700 is expensive based on its Price-To-Sales Ratio (4.5x) compared to the European Healthcare Services industry average (2.2x).

Price to Sales Ratio vs Fair Ratio

What is 700's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

700 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 700's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 700 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€13.56
0%
12.7%€16.15€11.40n/a9
Nov ’25n/a
€14.95
0%
12.0%€18.37€11.94n/a9
Oct ’25n/a
€15.72
0%
11.5%€19.23€13.74n/a9
Sep ’25n/a
€15.72
0%
11.5%€19.23€13.74n/a9
Aug ’25n/a
€17.28
0%
11.7%€19.27€14.22n/a9
Jul ’25n/a
€18.22
0%
11.8%€21.49€14.48n/a9
Jun ’25n/a
€18.14
0%
10.4%€21.15€14.26n/a9
May ’25n/a
€18.18
0%
9.8%€21.19€14.28n/a10
Apr ’25n/a
€17.83
0%
8.7%€19.32€14.26n/a9
Mar ’25n/a
€17.82
0%
9.2%€19.38€14.30n/a8
Feb ’25n/a
€17.07
0%
12.5%€19.30€12.86n/a7
Jan ’25n/a
€16.75
0%
13.6%€19.24€12.82n/a7
Dec ’24n/a
€16.08
0%
12.6%€19.69€13.13n/a7
Nov ’24n/a
€17.54
0%
9.5%€19.83€15.11n/a7
Oct ’24n/a
€17.92
0%
13.5%€22.46€14.97n/a7
Sep ’24n/a
€17.80
0%
12.9%€22.04€14.70n/a8
Aug ’24€16.70
€21.26
+27.3%
13.6%€24.62€16.41n/a8
Jul ’24€18.60
€21.65
+16.4%
12.9%€24.76€16.51n/a9
Jun ’24€19.10
€22.65
+18.6%
10.3%€25.54€18.24n/a9
May ’24€21.60
€22.34
+3.4%
10.6%€25.35€18.11n/a9
Apr ’24€21.60
€21.73
+0.6%
10.1%€24.89€18.44n/a7
Mar ’24€16.80
€19.87
+18.3%
10.1%€23.89€17.46n/a8
Feb ’24€17.50
€19.87
+13.6%
10.1%€23.89€17.46n/a8
Jan ’24€14.90
€19.48
+30.7%
13.3%€24.34€15.91n/a8
Dec ’23€16.00
€19.85
+24.1%
14.6%€25.10€16.41n/a8
Nov ’23€12.20
€22.70
+86.0%
15.4%€28.32€17.20n/a8

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-8.8%

1Y

-37.3%

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-5.5%

1Y

18.9%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%